{"product_id":"tesamorelin-10mg","title":"Tesamorelin 10mg","description":"\u003ch2\u003eTesamorelin overview\u003c\/h2\u003e\n\u003cp class=\"\"\u003eTesamorelin is a \u003cstrong\u003esynthetic analog of growth hormone–releasing hormone (GHRH)\u003c\/strong\u003e designed to stimulate the pituitary to release \u003cstrong\u003eendogenous growth hormone (GH)\u003c\/strong\u003e, which then increases \u003cstrong\u003eIGF-1\u003c\/strong\u003e production downstream.\u003c\/p\u003e\n\u003ch2\u003eBody-composition and metabolic effects\u003c\/h2\u003e\n\u003ch3\u003eSelective reduction in visceral fat (VAT)\u003c\/h3\u003e\n\u003cp class=\"\"\u003eRandomized, placebo-controlled Phase 3 studies showed tesamorelin \u003cstrong\u003eselectively reduces VAT\u003c\/strong\u003e (commonly reported around ~15% over ~26 weeks) with much less effect on subcutaneous fat or overall body weight. (\u003ca href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa072375?utm_source=chatgpt.com\" title=\"Metabolic Effects of a Growth Hormone–Releasing Factor ...\"\u003eNew England Journal of Medicine\u003c\/a\u003e)\u003c\/p\u003e\n\u003ch3\u003eLonger-term data and durability\u003c\/h3\u003e\n\u003cp class=\"\"\u003ePublished analyses and extensions report VAT reductions maintained with continued therapy (e.g., through ~52 weeks in studied cohorts), and note that \u003cstrong\u003eVAT can rebound after discontinuation\u003c\/strong\u003e—so results may not persist if treatment stops. (\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11365754\/?utm_source=chatgpt.com\" title=\"Efficacy and Safety of Tesamorelin in People with HIV on ...\"\u003ePMC\u003c\/a\u003e)\u003c\/p\u003e\n\u003ch3\u003eLiver fat and metabolic markers (evidence base evolving)\u003c\/h3\u003e\n\u003cp class=\"\"\u003eBeyond VAT, tesamorelin has been studied for metabolic and hepatic endpoints in HIV populations, including effects on body composition and liver fat in some trial designs and syntheses of randomized evidence. (\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41545261\/?utm_source=chatgpt.com\" title=\"Body composition, hepatic fat, metabolic, and safety ...\"\u003ePubMed\u003c\/a\u003e)\u003c\/p\u003e\n\u003ch2\u003eHow tesamorelin works\u003c\/h2\u003e\n\u003cp class=\"\"\u003eTesamorelin binds \u003cstrong\u003eGHRH receptors in the pituitary\u003c\/strong\u003e, increasing pulsatile GH secretion and raising \u003cstrong\u003eIGF-1\u003c\/strong\u003e levels. This endocrine shift is understood to contribute to its VAT-reducing effects in the HIV lipodystrophy indication. (\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548730\/?utm_source=chatgpt.com\" title=\"Tesamorelin - LiverTox - NCBI Bookshelf\"\u003eNCBI\u003c\/a\u003e)\u003c\/p\u003e\n\u003ch2\u003eSafety and use limitations\u003c\/h2\u003e\n\u003cp class=\"\"\u003eKey label points include:\u003c\/p\u003e\n\u003cul data-rte-list=\"default\"\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003eIndicated for \u003cstrong\u003ereduction of excess abdominal fat\u003c\/strong\u003e in HIV-infected adults with lipodystrophy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003e\u003cstrong\u003eNot indicated for weight-loss management\u003c\/strong\u003e (described as weight-neutral).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003e\u003cstrong\u003eLong-term cardiovascular safety has not been established\u003c\/strong\u003e; continuation should be weighed against benefit if VAT reduction is not achieved. (\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/022505s020lbl.pdf?utm_source=chatgpt.com\" title=\"FULL PRESCRIBING INFORMATION - accessdata.fda.gov\"\u003eFDA Access Data\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eTesamorelin specifications\u003c\/h2\u003e\n\u003cul data-rte-list=\"default\"\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003e\u003cstrong\u003eCAS Number:\u003c\/strong\u003e 218949-48-5 (\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Tesamorelin?utm_source=chatgpt.com\" title=\"Tesamorelin | C221H366N72O67S | CID 16137828 - PubChem\"\u003ePubChem\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₂₂₁H₃₆₆N₇₂O₆₇S (\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Tesamorelin?utm_source=chatgpt.com\" title=\"Tesamorelin | C221H366N72O67S | CID 16137828 - PubChem\"\u003ePubChem\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003e\u003cstrong\u003ePeptide class\/length:\u003c\/strong\u003e synthetic \u003cstrong\u003eGHRH analog\u003c\/strong\u003e (44-amino-acid peptide backbone, with stabilizing modification) (\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548730\/?utm_source=chatgpt.com\" title=\"Tesamorelin - LiverTox - NCBI Bookshelf\"\u003eNCBI\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003e\u003cstrong\u003eCommon form (brand):\u003c\/strong\u003e sterile powder for injection (EGRIFTA products); administered subcutaneously per label (\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/022505s020lbl.pdf?utm_source=chatgpt.com\" title=\"FULL PRESCRIBING INFORMATION - accessdata.fda.gov\"\u003eFDA Access Data\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch1\u003eReferences\u003c\/h1\u003e\n\u003col data-rte-list=\"default\"\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003e\u003cstrong\u003eFDA Prescribing Information (EGRIFTA WR)\u003c\/strong\u003e – indications, limitations, and safety statements. (\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/022505s020lbl.pdf?utm_source=chatgpt.com\" title=\"FULL PRESCRIBING INFORMATION - accessdata.fda.gov\"\u003eFDA Access Data\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003eFalutz J, et al. \u003cstrong\u003eMetabolic Effects of a Growth Hormone–Releasing Factor Analog for HIV-Associated Abdominal Fat Accumulation\u003c\/strong\u003e (\u003cem\u003eNEJM\u003c\/em\u003e, 2007) – pivotal randomized trial evidence for VAT reduction. (\u003ca href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa072375?utm_source=chatgpt.com\" title=\"Metabolic Effects of a Growth Hormone–Releasing Factor ...\"\u003eNew England Journal of Medicine\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003eFourman LT, et al. \u003cstrong\u003eVisceral Fat Reduction with Tesamorelin…\u003c\/strong\u003e (\u003cem\u003eopen-access review\/analysis\u003c\/em\u003e, 2017) – summarizes Phase 3 VAT effects and related outcomes. (\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5633509\/?utm_source=chatgpt.com\" title=\"Visceral Fat Reduction with Tesamorelin Is Associated ...\"\u003ePMC\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003eRusso SC, et al. \u003cstrong\u003eEfficacy and Safety of Tesamorelin in People with HIV…\u003c\/strong\u003e (\u003cem\u003eopen-access\u003c\/em\u003e, 2024) – modern synthesis\/overview of VAT reduction magnitudes and safety context. (\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11365754\/?utm_source=chatgpt.com\" title=\"Efficacy and Safety of Tesamorelin in People with HIV on ...\"\u003ePMC\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003eNCBI Bookshelf (LiverTox). \u003cstrong\u003eTesamorelin\u003c\/strong\u003e – mechanism (GHRH receptor → GH → IGF-1) and clinical context. (\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548730\/?utm_source=chatgpt.com\" title=\"Tesamorelin - LiverTox - NCBI Bookshelf\"\u003eNCBI\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003eClinicalTrials.gov. \u003cstrong\u003eTH9507 extension study\u003c\/strong\u003e – trial design details including CT-based VAT assessment through ~52 weeks. (\u003ca href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT00608023?utm_source=chatgpt.com\" title=\"TH9507 Extension Study in Patients With HIV-Associated ...\"\u003eClinicalTrials.gov\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003eNIH PubChem. \u003cstrong\u003eTesamorelin compound record\u003c\/strong\u003e – CAS and molecular formula. (\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Tesamorelin?utm_source=chatgpt.com\" title=\"Tesamorelin | C221H366N72O67S | CID 16137828 - PubChem\"\u003ePubChem\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003e\u003cstrong\u003eComplete Disclaimer\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\"\u003eThis product is sold exclusively for laboratory research purposes under Section 351 of the Public Health Service Act. It is not intended for human or veterinary use, nor for diagnostic, therapeutic, or cosmetic applications. Purchaser certifies they are properly licensed and equipped to handle research compounds in compliance with all local, state, and federal regulations. EaglePeptidesUSA assumes no liability for misuse or unauthorized handling. By purchasing, you affirm this material will not be introduced into interstate commerce or used in food\/drug products.\u003c\/p\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":53220093297004,"sku":null,"price":95.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0978\/1539\/6716\/files\/TESAEAGLEUSABackgroundRemoved.png?v=1772478131","url":"https:\/\/eaglepeptidesusa.com\/products\/tesamorelin-10mg","provider":"Eagle Peptides","version":"1.0","type":"link"}